Table 4.
CHM prescription | Chronic hepatitis | Hazard ratio (95% CI) | ||
---|---|---|---|---|
N | Number of events | Crude∗ | Adjusted† | |
Non-TCM user | 6928 | 442 | 1 (reference) | 1 (reference) |
CHM user: single herb | ||||
Hedyotis diffusa | 1809 | 104 | 0.68 (0.55–0.84)∗∗∗ | 0.51 (0.41–0.63)∗∗∗ |
Taraxacum officinale | 2161 | 117 | 0.64 (0.52–0.78)∗∗∗ | 0.46 (0.37–0.57)∗∗∗ |
Scutellaria barbata | 1416 | 81 | 0.64 (0.50–0.81)∗∗∗ | 0.47 (0.37–0.60)∗∗∗ |
Spatholobus suberectus | 1640 | 91 | 0.66 (0.53–0.83)∗∗∗ | 0.48 (0.38–0.61)∗∗∗ |
Salvia miltiorrhiza | 1706 | 110 | 0.71 (0.58–0.88)∗∗ | 0.53 (0.43–0.65)∗∗∗ |
Zizyphi Spinosi Semen | 1578 | 84 | 0.60 (0.47–0.76)∗∗∗ | 0.45 (0.35–0.57)∗∗∗ |
Astragalus membranaceus | 1716 | 111 | 0.74 (0.60–0.91)∗∗ | 0.54 (0.44–0.67)∗∗∗ |
Rhei Rhizoma | 957 | 36 | 0.44 (0.32–0.62)∗∗∗ | 0.33 (0.23–0.46)∗∗∗ |
Polygonum multiflorum Thunb. | 1383 | 81 | 0.68 (0.54–0.86)∗∗ | 0.53 (0.41–0.67)∗∗∗ |
Fritillaria thunbergii Miq. | 1467 | 67 | 0.52 (0.40–0.68)∗∗∗ | 0.40 (0.31–0.52)∗∗∗ |
CHM user: formula | ||||
Jia-Wei-Xiao-Yao-San | 2814 | 180 | 0.69 (0.58–0.83)∗∗∗ | 0.55 (0.46–0.65)∗∗∗ |
Xiang-Sha-Liu-Jun-Zi-Tang | 1549 | 98 | 0.73 (0.58–0.91)∗∗ | 0.54 (0.43–0.68)∗∗∗ |
San-Zhong-Kui-Jian-Tang | 879 | 47 | 0.66 (0.49–0.90)∗∗ | 0.50 (0.37–0.67)∗∗∗ |
Suan-Zao-Ren-Tang | 1253 | 69 | 0.62 (0.48–0.80)∗∗∗ | 0.48 (0.37–0.62)∗∗∗ |
Gui-Pi-Tang | 1369 | 76 | 0.65 (0.51–0.83)∗∗∗ | 0.49 (0.38–0.63)∗∗∗ |
Zhen-Ren-Huo-Ming-Yin | 935 | 36 | 0.45 (0.32–0.63)∗∗∗ | 0.34 (0.24–0.47)∗∗∗ |
Bu-Zhong-Yi-Qi-Tang | 1356 | 84 | 0.69 (0.55–0.88)∗∗ | 0.53 (0.42–0.67)∗∗∗ |
Zhi-Bai-Di-Huang-Wan | 1142 | 69 | 0.69 (0.53–0.88)∗∗ | 0.52 (0.40–0.67)∗∗∗ |
Xue-Fu-Zhu-Yu-Tang | 1101 | 56 | 0.58 (0.44–0.76)∗∗∗ | 0.45 (0.34–0.59)∗∗∗ |
Sheng-Mai-Yin | 1147 | 61 | 0.63 (0.48–0.82)∗∗∗ | 0.47 (0.36–0.62)∗∗∗ |
Crude HR∗ represented relative hazard ratio; adjusted HR† represented adjusted hazard ratio: mutually adjusted for Chinese herb used, age, CCI score, treatment, and lag time in Cox proportional hazard regression. Lag time was defined as the duration between first diagnosis breast cancer dates and first accepted Chinese herb medicine date during the follow-up period. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.